On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Stratec Biomedical AG Gemini. This instrumentation change is necessary as Bio-Rad is discontinuing service on our existing QuickStep instrumentation.
Although the Immucor assay and sample requirements will remain the same, the package insert has been modified to state the assay is specific to the Stratec Gemini instrument. The new package insert, assay history list, and platform history list will be available on the CTS website on 04/29/19.
On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the changes to F...
We have now added a new section called the "Assay History List" to the "At A Gla...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...